Search results for "Tetrazole"
showing 10 items of 70 documents
CCDC 251393: Experimental Crystal Structure Determination
2004
Related Article: J.Kusz, H.Spiering, P.Gutlich|2004|J.Appl.Crystallogr.|37|589|doi:10.1107/S0021889804011720
CCDC 251394: Experimental Crystal Structure Determination
2004
Related Article: J.Kusz, H.Spiering, P.Gutlich|2004|J.Appl.Crystallogr.|37|589|doi:10.1107/S0021889804011720
CCDC 866767: Experimental Crystal Structure Determination
2012
Related Article: J.Kusz, M.Zubko, R.B.Neder, P.Gutlich|2012|Acta Crystallogr.,Sect.B:Struct.Sci.|68|40|doi:10.1107/S0108768111053298
CCDC 866765: Experimental Crystal Structure Determination
2012
Related Article: J.Kusz, M.Zubko, R.B.Neder, P.Gutlich|2012|Acta Crystallogr.,Sect.B:Struct.Sci.|68|40|doi:10.1107/S0108768111053298
CCDC 866766: Experimental Crystal Structure Determination
2012
Related Article: J.Kusz, M.Zubko, R.B.Neder, P.Gutlich|2012|Acta Crystallogr.,Sect.B:Struct.Sci.|68|40|doi:10.1107/S0108768111053298
CCDC 866764: Experimental Crystal Structure Determination
2012
Related Article: J.Kusz, M.Zubko, R.B.Neder, P.Gutlich|2012|Acta Crystallogr.,Sect.B:Struct.Sci.|68|40|doi:10.1107/S0108768111053298
Cilostazol and atherogenic dyslipidemia: a clinically relevant effect
2011
Cilostazol is a reversible, selective inhibitor of PDE3A able to significantly improve walking distance in patients with intermittent claudication. However, beyond its antiplatelet and vasodilator properties, cilostazol seems to have significant effects on atherogenic dyslipidemia.The effects of cilostazol on plasma lipids, lipoproteins, apolipoproteins and postprandial lipemia are reviewed. A literature search (using Medline and Scopus) was performed up to 24 October 2010. The authors also manually reviewed the references of selected articles for any pertinent material.Cilostazol is able to significantly lower plasma triglyceride levels, with a concomitant increase in high-density lipoprot…
The nephroprotective effect of sacubitril/valsartan in heart failure: insights from the real-life clinical setting
2019
Real-life data confirming the favourable renal outcome in patients with heart failure (HF) treated with Sacubitril/Valsartan, previously found in several trials (RCTs), are still scant. We evaluated the renal effects of Sacubitril/Valsartan in a real-life sample of HF patients. Observational analysis of 54 consecutive outpatients affected by HF with reduced ejection fraction (HFrEF) and clinical indication for Sacubitril/Valsartan. Patients were evaluated at baseline (T0) and after six (T6) and twelve (T12) months after initiating Sacubitril/Valsartan and compared with a group of 30 historical controls. Mean age: 65.5 ± 11.7 years. Older patients: 29 (53.7%). Mean baseline estimated glomeru…
Determination of glyphosate and its metabolite aminomethylphosphonic acid in fruit juices using supported-liquid membrane preconcentration method wit…
2005
Abstract The application of supported-liquid membrane (SLM) technique for effective extraction of N -(phosphonomethyl)glycine (glyphosate) and its primary metabolite aminomethylphosphonic acid (AMPA) from juices (orange, grapefruit, apple and blackcurrant) in combination with HPLC-UV detection after derivatization with p -toluenesulphonyl chloride (TsCl) is presented. The influence of various parameters such as the composition of acceptor phase, flow-rate, concentration of analytes, on the performance of extraction procedure, was studied. It was shown that by appropriate manipulation of SLM parameters the level of detection could be significantly improved. The influence of SLM conditions on…
N-[3-Methyl-1-phenyl-1-(1H-tetrazol-1-yl)butan-2-yl]acetamide
2016
In the molecule of the title compound, C14H19N5O, the dihedral angle formed between the tetrazole and phenyl rings is 68.39 (4)°. In the crystal, molecules are linked by N—H...N, C—H...N and C—H...O hydrogen bonds to form two-dimensional networks extending parallel to thebcplane.